ストックスクリーナーアプリを入手
14.35
4.59%
0.63
アフターアワーズ：
14.35
Silence Therapeutics Plc Adr (SLN) 最新ニュース
Investors Buy High Volume of Silence Therapeutics Call Options (NASDAQ:SLN) - MarketBeat
Silence Therapeutics closes $201.3M public offering By Investing.com - Investing.com India
Silence Therapeutics closes $201.3M public offering - Investing.com
Silence Therapeutics Director Richard Ian Griffiths Reports Multiple ADS Sales on August 10, 2026 - Kalkine Media
Wall Street Analysts Predict a 140.06% Upside in Silence Therapeutics (SLN): Here's What You Should Know - Yahoo Finance
Silence Therapeutics Announces Pricing of $13.50 Per ADS in Public Offering - Kalkine Media
Form 8K Silence Therapeutics plc For: 12 August By Investing.com - Investing.com India
Silence Therapeutics (NASDAQ:SLN) Shares Down 6.9%What's Next? - MarketBeat
Silence Therapeutics prices $175M public offering at $13.50 per ADS - Investing.com
Why Avalon Holdings Shares Are Trading Higher By More Than 10%; Here Are 20 Stocks Moving Premarket - Sahm
Silence Therapeutics (NASDAQ:SLN) Sees Unusually-High Trading VolumeWhat's Next? - MarketBeat
Silence Therapeutics’ Divesiran Hits Phase II Goal, Sets Up Phase III PV Trial - sharewise.com
Silence Therapeutics Jumps Over 25% After Divesiran Phase 2 Trial Supports 12-Week Dosing - TechStock²
Silence Therapeutics launches $150 million public offering - Investing.com
Silence Therapeutics launches $150 million public offering By Investing.com - Investing.com India
Silence Therapeutics (NASDAQ:SLN) Shares Gap UpStill a Buy? - MarketBeat
Silence Therapeutics Reports Q2 2026 Financial Results in SEC Filing - Kalkine Media
Silence Therapeutics Announces Positive Phase 2 SANRECO Trial Outcomes for Divesiran in Polycythemia Vera - Kalkine Media
Silence Therapeutics SLN Stock Heats Up Ahead Phase 2 Data - StocksToTrade
Silence Therapeutics (SLN) Rallies Ahead Of Key Phase 2 Data - timothysykes.com
Silence Therapeutics reports positive phase 2 trial results - Investing.com
Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile - Finviz
Why is Silence Therapeutics stock surging today? By Investing.com - Investing.com South Africa
Silence Therapeutics (NASDAQ:SLN) Reaches New 1-Year HighStill a Buy? - MarketBeat
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
ADAR1 Capital Management LLC Buys 148,514 Shares of Silence Therapeutics PLC Sponsored ADR $SLN - MarketBeat
Silence Therapeutics (NASDAQ:SLN) Sees Large Volume IncreaseStill a Buy? - MarketBeat
Silence Therapeutics (NASDAQ:SLN) Reaches New 12-Month HighTime to Buy? - MarketBeat
Silence Therapeutics (NASDAQ:SLN) Stock Price Up 6.9%Here's Why - MarketBeat
SLN stock skyrockets 107% in six months: Here's what you need to know - MSN
Silence Therapeutics (SLN) moves 7.2% higher: Will this strength last? - MSN
ETFs Investing in Silence Therapeutics PLC Sponsored ADR Stocks - TradingView
SLN Stock Skyrockets 107% in Six Months: Here's What You Need to Know - Yahoo Finance UK
Silence Therapeutics (SLN) Moves 7.2% Higher: Will This Strength Last? - Yahoo Finance Singapore
Silence Therapeutics (NASDAQ:SLN) Shares Up 10%Here's What Happened - MarketBeat
Form 13D/A Silence Therapeutics Plc For: 8 July By Investing.com - Investing.com South Africa
Silence Therapeutics (SLN) surges 26.0%: Is this an indication of further gains? - MSN
Silence Therapeutics PLC Sponsored ADR Actuals & Estimates (NASDAQ:SLN) - TradingView
Silence Therapeutics (SLN) Surges 26.0%: Is This an Indication of Further Gains? - Yahoo Finance Singapore
Why is Silence Therapeutics stock surging today? - Investing.com
Silence Therapeutics stock jumps on Cantor Fitzgerald upgrade - Investing.com
Form 8K Silence Therapeutics plc For: 23 June By Investing.com - Investing.com Australia
H.C. Wainwright reiterates Silence Therapeutics stock rating at buy By Investing.com - Investing.com India
H.C. Wainwright reiterates Silence Therapeutics stock rating at buy - Investing.com
Silence Therapeutics Stock Rises On Positive Blood Cancer Drug Data - Sahm
Silence Therapeutics presents divesiran trial data at EHA By Investing.com - Investing.com South Africa
Silence Therapeutics presents divesiran trial data at EHA - Investing.com
Silence Therapeutics (SLN) soars 19.0%: Is further upside left in the stock? - MSN
SLNSilence Therapeutics Plc ADR Stock Price and Quote - Finviz
Silence Therapeutics (NASDAQ: SLN) registers $300M shelf, $100M ADSs included - Stock Titan
Silence Therapeutics to Participate in H.C. Wainwright BioConnect Investor Conference - ChartMill
Revenue per share of Silence Therapeutics PLC Sponsored ADR – DUS:XRP2 - TradingView
Book value per share of Silence Therapeutics PLC Sponsored ADR – DUS:XRP2 - TradingView
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Short Interest Up 13.3% in April - MarketBeat
1.80%
1.77%
大文字化:
|
ボリューム (24 時間):